Selank
Also called TP-7, Thr-Lys-Pro-Arg-Pro-Gly-Pro.
Selank has no FDA-approved product. This page cites 2 sources, and the strongest evidence comes from human trials.
- Status
- No FDA-approved product
- Form
- Nasal spray
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 2
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
A Russian randomized comparison in 62 patients with generalized anxiety disorder or neurasthenia reported similar anxiety-scale improvement with Selank and medazepam, an active benzodiazepine comparator.
Limits: The accessible English abstract describes 30 Selank and 32 medazepam recipients, without a placebo arm or enough detail to assess blinding and duration. Similar reported scores do not establish statistical equivalence, long-term safety, or efficacy of N-acetyl Selank.
Animal studies
A rat experiment using intranasal Selank and oral diazepam found that anxiety-related maze responses depended on stress exposure and whether the agents were given separately or together.
Limits: The experiment measured rat behaviors over 14 days. It did not measure anxiety treatment outcomes in people. Findings do not validate a human combination, an injectable formulation, or N-acetyl and amidated Selank variants.
Regulatory status
United States
No FDA-approved product was identified. FDA lists Selank acetate among withdrawn nominations and describes unresolved safety information, possible immunogenicity, and peptide-impurity concerns. That listing does not establish approval or unrestricted compounding eligibility. Selank is absent from the October 2026 HHS policy appendix.